Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Invitrx Therapeutics Inc.
WARNING LETTER
•Invitrx Therapeutics Inc.•April 3, 2019

Invitrx Therapeutics Inc. – FDA Warning Letter, Apr 3, 2019

Record Details

On March 16, 2020, the FDA issued a Warning Letter to Invitrx Therapeutics, Inc. following an inspection from March 25 to April 3, 2019. The inspection revealed that Invitrx processes and distributes allogeneic products, including human umbilical cord blood, umbilical cord-derived products (Invitra CBSCTM, Invitra WJTM), amniotic fluid-derived product (Invitra AFTM), and amniotic membrane-derived product (Invitra ATTM). These products are intended for injection and purported to be sterile, marketed for various conditions, thus classifying them as drugs and biological products under the FD&C Act and PHS Act. Some are also HCT/Ps.

Invitrx's products do not qualify for exceptions under 21 CFR 1271.15 and fail to meet criteria in 21 CFR 1271.10(a), specifically regarding homologous use, minimal manipulation, and metabolic activity. Consequently, they are regulated as drugs and biological products requiring an approved Biologics License Application (BLA) or an Investigational New Drug (IND) application, neither of which Invitrx possesses.

The inspection also identified significant deviations from Current Good Manufacturing Practice (CGMP) and Current Good Tissue Practice (CGTP), posing safety concerns due to potential contamination. Deficiencies include: - Failure to determine and document donor eligibility (21 CFR 1

Company
Invitrx Therapeutics Inc.
Inspection date
April 3, 2019
Product type
Biologics
Office
Center for Biologics Evaluation and Research
People
  • Daniel W. Cline
  • Karlton T. Watson (Program Division Director)
View Company Profile

ID · 609c196c-c4a1-4fb7-80a4-7aff1231849d

Violation Codes10
FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)21 U.S.C. 321(g)21 U.S.C. 355(i)21 CFR 127121 CFR 1271.3(d)21 CFR 1271.10(a)21 CFR 1271.1521 CFR 1271.l0(a)21 CFR 1271.10(a)(2)

Full citation text and observation details available on the Dashboard.

Other documents for Invitrx Therapeutics Inc.
  • 483 - 2025-04-30April 30, 2025
  • 483 - 2022-03-22March 22, 2022

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Invitrx Therapeutics Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.